Howe Jolanda 4

What Happened

• Jolanda Howe, SVP and Global Controller of Mirum Pharmaceuticals (MIRM), had 1,542 restricted stock units convert to common stock on Jan 21, 2026. Following the conversion, 926 shares were sold in the open market on Jan 22, 2026 at $93.33 per share for proceeds of $86,419.
• The filing also records a derivative disposition associated with the conversion/settlement (reported at $0), which reflects shares surrendered/withheld for tax purposes tied to the RSU vesting.

Key Details

• Transaction dates and prices:
  • Jan 21, 2026: 1,542 RSUs converted to 1,542 shares (exercise/conversion of derivative).
  • Jan 22, 2026: Open-market sale of 926 shares at $93.33 each — proceeds $86,419.
  • Jan 21, 2026: Derivative disposition reported at $0 (related to tax withholding/settlement).
• Shares owned after the transaction: not specified in this filing.
• Footnotes:
  • F1: Each RSU converts to one share (or cash equivalent at issuer's discretion).
  • F2: Shares were sold to cover tax withholding obligations from RSU vesting.
  • F3: RSUs vest 1/3 each year starting Jan 21, 2025 (three-year schedule).
• Filing: Form 4 filed Jan 23, 2026 covering Jan 21–22 transactions; the filing shows the routine vesting/tax-withholding mechanics rather than a standalone market purchase.

Context

• This was a routine vesting and sell-to-cover tax event: RSUs converted to shares and a portion was sold to satisfy withholding. Such sales are common after RSU vesting and do not by themselves indicate a change in personal view about the company. Purchases are generally more informative about insider sentiment than routine tax-related sales.